Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease

Pharmacotherapy

Volumn 27, Issue 12 I, 2007, Pages 1627-1636

  Krishna, Gopal ^a   Martinho, Monika ^a   Chandrasekar, Pranatharthi ^b   Ullmann, Andrew J ^c   Patino, Hernando ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Azole; Graft versus host disease; GVHD; Hematopoietic stem cell transplant; HSCT; Invasive fungal infection; Pharmacokinetics; Posaconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FLUCONAZOLE; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSACONAZOLE; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MULTICENTER STUDY; MYCOSIS; PUVA; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIBIOTICS, ANTIFUNGAL; BODY WEIGHT; CHRONIC DISEASE; CONTINENTAL POPULATION GROUPS; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYCOSES; OPPORTUNISTIC INFECTIONS; SEX FACTORS; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 36849064207     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.12.1627     Document Type: Article

References (39)

1. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-6.
2. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract 2004;58:612-24.
3. van Burik J-AH, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases [online exclusive article]. Clin Infect Dis 2006;42:e61-5. Available from http://www.journals.uchicago.edu/CID/journal/issues/v42n7/37906/ 37906.html. (Erratum in Clin Infect Dis 2006;43:1376.)
4. Pfaller MA, Messer SA, Hollis RJ, Jones RN, and the SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 2002;46:1032-7.
5. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001;45:857-69.
6. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003;47:3647-50.
7. Tobon A, Correa AL, Arango M, de Bedout C, Restrepo A. Posaconazole therapy for severe abdominal candidiasis: a case report. Rev Iberoam Micol 2004;21:79-81.
8. Tobón AM, Arango M, Fernandez D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003;36:1488-91.
9. Raad I, Chapman S, Bradsher R, et al. Posaconazole (POS) salvage therapy for invasive fungal infections (IFI). Poster presentation at the 44th interscience conference on antimicrobial agents and chemotherapy, Washington, DC, October 30-November 2, 2004.
10. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403.
11. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47.
12. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788-95.
13. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66.
14. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006;50:1993-9.
15. Krishna G, Sansone-Parsons A. Pharmacokinetics of posaconazole in healthy volunteers: a meta-analysis of five phase 1 studies. Presented at the 41st midyear clinical meeting and exhibition of the American Society of Health-System Pharmacists, Anaheim, CA, December 3-7, 2006.
16. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218-22.
17. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211-20.
18. Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007;51:495-502.
19. Ezzet F, Wexler D, Courtney R, et al. Comparative bioavailability of oral posaconazole (POS) in different dosage regimens: a population pharmacokinetic analysis. Presented at the 43rd annual interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 14-17, 2003.
20. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8.
21. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667-74.
22. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
23. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330:827-38.
24. Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005;45:185-92.
25. Courtney R, Martinho M, Lim J, Statkevich P, Hardalo C. Evaluation of the effect of age, weight, race, and gender on posaconazole plasma concentrations in HIV-infected patients. Presented at the 13th European congress of clinical microbiology and infectious diseases, Glasgow, Scotland, May 10-13, 2003.
26. Akpek G, Chinratanalab W, Lee LA, et al. Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant 2003;9:46-51.
27. Ferrara JLM, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol 2003;78:181-7.
28. Iqbal N, Salzman D, Lazenby AJ, Wilcox CM. Diagnosis of gastrointestinal graft-versus-host disease. Am J Gastroenterol 2000;95:3034-8.
29. Schulenburg A, Turetschek K, Wrba F, et al. Early and late gastrointestinal complications after myeloablative and nonmyeloablative allogeneic stem cell transplantation. Ann Hematol 2004;83:101-6.
30. Schering-Plough Research Institute. Data on file. Lafayette, NJ; 2001.
31. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12.
32. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
33. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989;32:103-8.
34. Denning DW, Tucker RM, Hostetler JS, Gill S, Stevens DA. Oral itraconazole therapy of cryptococcal meningitis and cryptococcosis in patients with AIDS. In: Van den Bossche H, Mackenzie DWR, Cauwenbergh G, et al, eds. Mycoses in AIDS patients. New York: Plenum Press, 1990:305-24.
35. Denning DW, Van Wye JE, Lewiston NJ, Stevens DA. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest 1991;100:813-19.
36. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59.
37. Schering-Plough Research Institute. Data on file. Kenilworth, NJ; 2007.
38. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006;50:1881-3.
39. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56.